These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 7707384)

  • 1. Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors.
    Fitzgerald JM; Ramchurren N; Rieger K; Levesque P; Silverman M; Libertino JA; Summerhayes IC
    J Natl Cancer Inst; 1995 Jan; 87(2):129-33. PubMed ID: 7707384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ras oncogene mutations in urine sediments of patients with bladder cancer.
    Buyru N; Tigli H; Ozcan F; Dalay N
    J Biochem Mol Biol; 2003 Jul; 36(4):399-402. PubMed ID: 12895299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection.
    Rieger-Christ KM; Mourtzinos A; Lee PJ; Zagha RM; Cain J; Silverman M; Libertino JA; Summerhayes IC
    Cancer; 2003 Aug; 98(4):737-44. PubMed ID: 12910517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening of human bladder tumors and urine sediments for the presence of H-ras mutations.
    Levesque P; Ramchurren N; Saini K; Joyce A; Libertino J; Summerhayes IC
    Int J Cancer; 1993 Nov; 55(5):785-90. PubMed ID: 7902340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of urinary NMP-22 combined with urine cytology in follow-up surveillance of recurring superficial bladder urothelial carcinoma.
    Mansoor I; Calam RR; Al-Khafaji B
    Anal Quant Cytol Histol; 2008 Feb; 30(1):25-32. PubMed ID: 18459584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation of H-ras is infrequent in bladder cancer: confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing.
    Knowles MA; Williamson M
    Cancer Res; 1993 Jan; 53(1):133-9. PubMed ID: 8093230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases.
    Castillo-Martin M; Collazo Lorduy A; Gladoun N; Hyun G; Cordon-Cardo C
    J Pediatr Urol; 2016 Apr; 12(2):91.e1-7. PubMed ID: 26522772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples.
    Renard I; Joniau S; van Cleynenbreugel B; Collette C; Naômé C; Vlassenbroeck I; Nicolas H; de Leval J; Straub J; Van Criekinge W; Hamida W; Hellel M; Thomas A; de Leval L; Bierau K; Waltregny D
    Eur Urol; 2010 Jul; 58(1):96-104. PubMed ID: 19674832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urine cell-based DNA methylation classifier for monitoring bladder cancer.
    van der Heijden AG; Mengual L; Ingelmo-Torres M; Lozano JJ; van Rijt-van de Westerlo CCM; Baixauli M; Geavlete B; Moldoveanud C; Ene C; Dinney CP; Czerniak B; Schalken JA; Kiemeney LALM; Ribal MJ; Witjes JA; Alcaraz A
    Clin Epigenetics; 2018; 10():71. PubMed ID: 29854012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
    Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
    Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Microsatellite analysis in exfoliated cells from urinary sediment. Its utility for the detection of bladder cancer. Comparison with urinary cytology].
    Molina Burgos R; Millán Salvador JM; Oltra Soler JS; Jiménez Cruz JF
    Actas Urol Esp; 2003 Sep; 27(8):618-28. PubMed ID: 14587237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer.
    Trenti E; D'Elia C; Mian C; Schwienbacher C; Hanspeter E; Pycha A; Kafka M; Degener S; Danuser H; Roth S; Pycha A
    Cancer Cytopathol; 2019 Jul; 127(7):465-469. PubMed ID: 31154670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.
    Critelli R; Fasanelli F; Oderda M; Polidoro S; Assumma MB; Viberti C; Preto M; Gontero P; Cucchiarale G; Lurkin I; Zwarthoff EC; Vineis P; Sacerdote C; Matullo G; Naccarati A
    Oncotarget; 2016 Oct; 7(41):67435-67448. PubMed ID: 27611947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokeratin 20 immunocytochemistry on urine sediments: A potential low-cost adjunct to cytology in the diagnosis of low-grade urothelial carcinoma.
    Wadhwa N; Diwaker P; Lotha N; Arora VK; Singh N
    Cytopathology; 2017 Dec; 28(6):531-535. PubMed ID: 28940433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer.
    Stasik S; Salomo K; Heberling U; Froehner M; Sommer U; Baretton GB; Ehninger G; Wirth MP; Thiede C; Fuessel S
    Clin Biochem; 2019 Feb; 64():60-63. PubMed ID: 30528938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of a comprehensive, urothelial carcinoma-specific next-generation sequencing panel in urine cytology and bladder tumor specimens.
    Sun T; Hutchinson L; Tomaszewicz K; Caporelli ML; Meng X; McCauley K; Fischer AH; Cosar EF; Cornejo KM
    Cancer Cytopathol; 2021 Jul; 129(7):537-547. PubMed ID: 33539671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression in transitional cell carcinoma of the urinary bladder--analysis of Tp53 gene mutations by temperature gradients and sequence in tumor tissues and in cellular urine sediments.
    Schlechte HH; Sachs MD; Lenk SV; Brenner S; Rudolph BD; Loening SA
    Cancer Detect Prev; 2000; 24(1):24-32. PubMed ID: 10757120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of H-ras mutations in urine sediments by a mutant-enriched PCR technique.
    Conejo JR; Parra T; Cantero M; Jiménez A; Granizo V; de Arriba G; Carballo F
    Clin Chem; 1998 Jul; 44(7):1570-2. PubMed ID: 9665446
    [No Abstract]   [Full Text] [Related]  

  • 20. The utility of Ki-ras mutation analysis in the cytologic diagnosis of pancreatobiliary neoplasma.
    Dillon DA; Johnson CC; Topazian MD; Tallini G; Rimm DL; Costa JC
    Cancer J; 2000; 6(5):294-301. PubMed ID: 11079168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.